Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on applying the SmartDepot microsphere formulation to peptide candidates, including GLP-1 agents and CNS programs. This stage explicitly excludes commercial rights and permits termination on 30 days’ notice, with no public disclosure of a binding licensing, technology transfer, or equivalent commercial deal despite nearly two years of in-vivo validation work. Recent developments, including Lilly’s separate long-acting formulation partnerships and Peptron’s focus on internal pipeline progress and manufacturing expansion, have reinforced trader consensus that a full commercial license is unlikely before the deadline.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於13% 機率
$11,414 交易量
$11,414 交易量
2026-10-06
13% 機率
$11,414 交易量
$11,414 交易量
2026-10-06
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on applying the SmartDepot microsphere formulation to peptide candidates, including GLP-1 agents and CNS programs. This stage explicitly excludes commercial rights and permits termination on 30 days’ notice, with no public disclosure of a binding licensing, technology transfer, or equivalent commercial deal despite nearly two years of in-vivo validation work. Recent developments, including Lilly’s separate long-acting formulation partnerships and Peptron’s focus on internal pipeline progress and manufacturing expansion, have reinforced trader consensus that a full commercial license is unlikely before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市場開放時間： May 5, 2026, 8:02 PM ET
交易量
$11,414結束日期
2026-10-07市場開放時間
May 5, 2026, 8:02 PM ETThis market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on applying the SmartDepot microsphere formulation to peptide candidates, including GLP-1 agents and CNS programs. This stage explicitly excludes commercial rights and permits termination on 30 days’ notice, with no public disclosure of a binding licensing, technology transfer, or equivalent commercial deal despite nearly two years of in-vivo validation work. Recent developments, including Lilly’s separate long-acting formulation partnerships and Peptron’s focus on internal pipeline progress and manufacturing expansion, have reinforced trader consensus that a full commercial license is unlikely before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$11,414結束日期
2026-10-07市場開放時間
May 5, 2026, 8:02 PM ETEli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on applying the SmartDepot microsphere formulation to peptide candidates, including GLP-1 agents and CNS programs. This stage explicitly excludes commercial rights and permits termination on 30 days’ notice, with no public disclosure of a binding licensing, technology transfer, or equivalent commercial deal despite nearly two years of in-vivo validation work. Recent developments, including Lilly’s separate long-acting formulation partnerships and Peptron’s focus on internal pipeline progress and manufacturing expansion, have reinforced trader consensus that a full commercial license is unlikely before the deadline.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions